Skip to main content

Concomitancy and Indications for Idelalisib Use

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    bendamustine
    bortezomib
    chlorambucil
    cyclophosphamide
    doxorubicin
    ibritumomab
    ibrutinib
    idelalisib
    lenalidomide
    obinutuzumab
    ofatumumab
    prednisone
    rituximab
    vincristine
    Description

    This report contains estimated numbers of idelalisib users and idelalisib users with concomitant use of several anti-cancer agents as well as cancer diagnoses around the time of idelalisib use. Data from July 23, 2014 to December 31, 2015 from 15 health plans contributing to the Sentinel Distributed Database (SDD) were included in this report. This request was distributed on May 19, 2016.

    Additional Details
    FDA Center
    CDER
    Time Period
    July 23, 2014 - December 31, 2015
    Analysis Type
    Descriptive
    Population / Cohort
    Individuals 18 years of age and older
    Data Sources
    Sentinel Distributed Database (SDD)